Integral PET, LLC is one of the the largest networks of positron emission tomography (PET) imaging services in the United States. Integral's network of mobile and fixed site PET centers can be found in academic and community hospitals and in freestanding settings, including several of the cancer centers affiliated with the University of Pennsylvania. All are community-oriented, with a special emphasis on patient care and physician service. Integral PET is committed to educating both the medical and patient community about the capabilities of positron emission tomography and its appropriate uses in the diagnosis and treatment of cancer, neurological conditions such as epilepsy and Alzheimer's disease, and in cardiology. Our mission is to bring high quality advanced diagnostic imaging technology to communities around the country.
Integral PET is a member of the Integral group of companies, whose members also include Integral Nuclear Associates, which operates nuclear imaging centers, primarily for cardiac-related procedures, in New York, New Jersey, Pennsylvania, Maryland and the District of Columbia. Integral is headquartered in New York City. For more information on PET and Integral PET please visit: www.integralpet.com.
Click on the image below to go to the web site maintained by
The Abramson Cancer Center of the University of Pennsylvania
is not responsible for that site's content.
Jul 1, 2010 - Immunosuppressive treatment with cyclosporine A, rather than tacrolimus, with dose level monitoring two hours post-dosing or in patients age 50 or younger appears to have a significant association with the development of de novo cancer after liver transplantation, according to research published in the July issue of Liver Transplantation.